| Title |
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
|
|---|---|
| Published in |
Neurotoxicity Research, October 2015
|
| DOI | 10.1007/s12640-015-9565-5 |
| Pubmed ID | |
| Authors |
Margherita Fabbri, Giorgio Leodori, Ricardo M. Fernandes, Roongroj Bhidayasiri, Maria Jose Marti, Carlo Colosimo, Joaquim J. Ferreira |
| Abstract |
The formation of neutralizing antibodies (NAbs) directed specifically against the active neurotoxin part of the botulinum neurotoxin (BoNT) complex is often cited as a major cause of secondary non-responsiveness (SnR) to treatment. This systematic and meta-analytic review evaluates the frequency of NAbs among patients treated with BoNT therapy for any clinical indication. A comprehensive database search strategy was designed to retrieve relevant clinical data from the published literature up to April 2013. All English-language publications that analyzed NAbs prevalence in more than ten patients were included, regardless of BoNT formulation, assay method, and study design. For the meta-analysis, patients were divided into three categories: secondary non-response (SnR) patients, clinically responding patients and all patients, independently of BoNT responsiveness. The meta-analysis included 61 studies reporting data for 8525 patients; 4972 dystonic patients, 1170 patients with spasticity, 294 patients with urologic indications, 396 patient with hyperhidrosis, 1659 patients with glabellar line, and 34 patients with hypersalivation. Among the "all patients" group NAbs frequency was 20 % for dystonia, 5.9 % for spasticity, and 2.7 % for urologic patients and 1.1 % for other conditions. The prevalence of NAbs was lower (3.5 %) among clinically responding patients and higher in 53.5 % SnR patients. About a half of patients with SnR do not have NAbs. NAbs was high among patients treated with RIMA but it was not associated with clinical non-responsiveness. Meta-analysis of the frequency of NAbs and SnR are limited by the heterogeneity of study design and reported outcomes. Indeed the analysis of several factors that can influence the development of NAbs, i.e., MHC of patients, frequency and site of injection, injection technique, cumulative dose, and toxin denaturation, was not specifically evaluated due to the paucity and heterogeneity of data. The identification of all these missing data should be taken into account in order to improve the methodology of future studies. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 12% |
| Student > Master | 8 | 12% |
| Student > Doctoral Student | 8 | 12% |
| Professor > Associate Professor | 5 | 7% |
| Student > Postgraduate | 4 | 6% |
| Other | 13 | 19% |
| Unknown | 22 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 44% |
| Neuroscience | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 18 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2015.
All research outputs
#17,775,656
of 22,830,751 outputs
Outputs from Neurotoxicity Research
#599
of 881 outputs
Outputs of similar age
#188,150
of 279,406 outputs
Outputs of similar age from Neurotoxicity Research
#10
of 18 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,406 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.